# Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

> **NCT02411084** · PHASE3 · TERMINATED · sponsor: **Adienne SA** · enrollment: 36 (actual)

## Conditions studied

- Graft vs Host Disease

## Interventions

- **BIOLOGICAL:** Begelomab
- **BIOLOGICAL:** Conventional Second-line Treatment

## Key facts

- **NCT ID:** NCT02411084
- **Lead sponsor:** Adienne SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02
- **Primary completion:** 2017-07-31
- **Final completion:** 2017-07-31
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Insufficient rate of accrual
- **Last updated:** 2020-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02411084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02411084, "Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02411084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*